|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
FY2011
12 months to Dec 31, 2011
|
|
|---|---|---|---|
| Cash and Cash Equivalents, Period Increase (Decrease) | |||
| Cash flows from operating activities: | |||
| Net income (loss) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | |||
| Depreciation | |||
| Amortization | |||
| Gain on sale of real estate | |||
| Share-based compensation | |||
| Note Receivable Impairment | |||
| Cease use loss | |||
| Change in fair value of contingent consideration liabilities | |||
| Contingent compensation expense | |||
| Amortization of premium on marketable debt securities | |||
| Amortization of discount on promissory notes receivable | |||
| Release of valuation allowance against deferred tax assets | |||
| Deferred income taxes | |||
| Excess tax benefit from exercise of stock options | |||
| Net gain on sale of cost method investment | |||
| Write-off of intangible asset in connection with the sale of intellectual property | |||
| Gain on sale of intellectual property | |||
| Unrealized losses on foreign currency forward contracts | |||
| Other | |||
| Changes in operating assets and liabilities: | |||
| Trade receivables | |||
| Prepaid expense and other current assets | |||
| Other assets | |||
| Accounts payable | |||
| Accrued liabilities, compensation and benefits | |||
| Deferred revenue | |||
| Net cash provided by operating activities | |||
| Cash flows from investing activities: | |||
| Acquisition of business, net of cash acquired | |||
| Cash paid for acquisitions, net of cash acquired | |||
| Deposit for business acquisitions | |||
| Equity issuance costs in connection with the Symyx Merger | |||
| Acquisition-related prepaid contingent compensation | |||
| Purchases of property and equipment, net | |||
| Net proceeds from sale of real estate | |||
| Purchases of marketable securities | |||
| Proceeds from maturities and sales of marketable securities | |||
| Net proceeds from sale of cost method investment | |||
| Proceeds from promissory notes receivable | |||
| Net decrease in restricted cash | |||
| Net cash provided by (used in) investing activities | |||
| Cash flows from financing activities: | |||
| Payment of contingent consideration liabilities | |||
| Proceeds from issuance of common stock | |||
| Common stock tendered for payment of withholding taxes | |||
| Excess tax benefit from exercise of stock options | |||
| Repurchases of common stock | |||
| Net cash (used in) provided by financing activities | |||
| Effect of changes in exchange rates on cash and cash equivalents | |||
| Increase (decrease) in cash and cash equivalents | |||
| Cash and cash equivalents at beginning of the year | |||
| Cash and cash equivalents at end of the year | |||
| Supplemental Cash Flow Elements | |||
| Supplemental cash flow information: | |||
| Cash (received) paid during the year for income taxes, net of refunds | |||
| Non-cash investing and financing activities: | |||
| Equity instruments issued in connection with Merger | |||
| Note receivable received in sale of intellectual property | |||
| Deferred gain on sale of intellectual property |
Loading...
